SSgA Funds Management, Inc. recently announced the acquisition of new stake in Aldeyra Therapeutics Inc (NASDAQ:ALDX). The institutional investor has increased its shareholding in the Healthcare company by 0.79% to 3.07 million shares with purchase of 24101.0 shares. This fresh investment now brings its stake to 5.21% valued currently at $8.49 million. In addition, The Vanguard Group, Inc. raised its holdings by 5777.0 to 3.06 million shares. And BlackRock Fund Advisors has lifted its position by 2.94% or 87190.0 shares – to 3.06 million shares.
Currently, there are 58.56M common shares owned by the public and among those 56.50M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 10 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 7 of these insider trades were purchases, accounting for 536,453 shares. Insider sales of the common stock occurred on 3 occasions, with total insider shares sold totaling 2,830,306 shares.
The top 3 mutual fund holders in Aldeyra Therapeutics Inc are SPDR S&P Biotech ETF, Vanguard Total Stock Market ETF, and iShares Russell 2000 ETF. SPDR S&P Biotech ETF owns 2.36 million shares of the company’s stock, all valued at over $6.54 million. The company bought an additional 11010.0 shares recently to bring their total holdings to about 4.01% of the shares outstanding. iShares Russell 2000 ETF bought 591.0 shares to bring its total holdings to over 1.2 million shares at a value of $3.34 million. iShares Russell 2000 ETF now owns shares totaling to 2.05% of the shares outstanding.
However, the script later moved the day high at 3.5800, up 18.58%. The company’s stock has a 5-day price change of 22.30% and -44.46% over the past three months. ALDX shares are trading -49.57% year to date (YTD), with the 12-month market performance down to -44.46% lower. It has a 12-month low price of $1.42 and touched a high of $11.97 over the same period. ALDX has an average intraday trading volume of 2.79 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 21.92%, 27.84%, and -50.14% respectively.
Institutional ownership of Aldeyra Therapeutics Inc (NASDAQ: ALDX) shares accounts for 59.36% of the company’s 58.56M shares outstanding. Mutual fund holders own 25.65%, while other institutional holders and individual stakeholders account for 38.29% and 21.09% respectively.
It has a market capitalization of $206.46M and a beta (3y monthly) value of 1.43. The earnings-per-share (ttm) stands at -$0.78. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.84% over the week and 9.13% over the month.
Analysts forecast that Aldeyra Therapeutics Inc (ALDX) will achieve an EPS of -$0.17 for the current quarter, -$0.18 for the next quarter and -$0.44 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.24 while analysts give the company a high EPS estimate of -$0.05. Comparatively, EPS for the current quarter was -$0.22 a year ago. Earnings per share for the fiscal year are expected to increase by 31.65%, and 48.38% over the next financial year.
Looking at the support for the ALDX, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on April 27, 2022, with the firm’s price target at $15.
